The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19
Phase NA Unknown
5,815 enrolled
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Phase 2 Unknown
50 enrolled
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
Phase NA Unknown
34 enrolled
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
Phase 2 Unknown
50 enrolled
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Phase 1 Unknown
22 enrolled
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Phase 1/2 Unknown
18 enrolled
FIL_KLIMT
Phase 2 Unknown
16 enrolled
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Phase 1/2 Unknown
60 enrolled
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Phase 2 Unknown
118 enrolled
PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years
Phase 4 Unknown
100 enrolled
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Phase 1 Unknown
87 enrolled
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
Phase 2 Unknown
100 enrolled
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Phase 3 Unknown
256 enrolled
RUE-DDGP
Phase 4 Unknown
30 enrolled
LYTPET
Phase 2 Unknown
150 enrolled
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Phase 2 Unknown
15 enrolled
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Phase 2 Unknown
50 enrolled
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Phase 3 Unknown
264 enrolled
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
Phase 2 Unknown
134 enrolled
VIDL+ASCT
Phase 2 Unknown
27 enrolled
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Phase 2 Unknown
29 enrolled
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Phase 2 Unknown
20 enrolled
ALL-MB 2015
Phase NA Unknown
4,000 enrolled
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Phase 2 Unknown
100 enrolled
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
Phase 3 Unknown
68 enrolled
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Phase 2/3 Unknown
80 enrolled
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Phase 2/3 Unknown
70 enrolled
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
Phase 4 Unknown
50 enrolled
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Phase 1 Unknown
72 enrolled
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Phase 2 Unknown
30 enrolled
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
Phase 2 Unknown
60 enrolled
BOMB-THROW
Phase 2 Unknown
15 enrolled
(R-HAD)
Phase 3 Unknown
128 enrolled
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Phase 4 Unknown
130 enrolled
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
Phase 4 Unknown
500 enrolled
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Phase 2 Unknown
30 enrolled
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
Phase NA Unknown
96 enrolled
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Unknown
180 enrolled
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
Phase 3 Unknown
100 enrolled
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Phase 3 Unknown
1,800 enrolled
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
Phase 2/3 Unknown
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma
Phase 3 Unknown
500 enrolled
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Phase 3 Unknown
200 enrolled
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
Phase 3 Unknown
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
Phase 3 Unknown
220 enrolled
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase NA Unknown
550 enrolled
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Phase 2 Unknown
30 enrolled
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Unknown
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Phase 3 Unknown
360 enrolled